Glycomimetics INC: management transactions · United States · SEC (Form 4)

About Glycomimetics INC

GlycoMimetics Inc. (ticker: GLYC) is a biotechnology company listed on the NASDAQ market in the United States (United States), focused on discovering and developing glycobiology-based therapies. From its headquarters in Rockville, Maryland, the company built its scientific positioning around a proprietary chemistry platform designed to create so-called glycomimetic molecules, which aim to modulate carbohydrate-mediated recognition pathways in serious diseases, particularly cancers and inflammatory conditions. Historically, GlycoMimetics has been a late-stage clinical biotech rather than a commercial-stage pharmaceutical company, with a research-driven model centered on a small number of internally developed drug candidates. ([ir.glycomimetics.com](https://ir.glycomimetics.com/?utm_source=openai)) The company was founded in the early 2000s and became known for its oncology programs, especially uproleselan, an E-selectin antagonist studied in acute myeloid leukemia and other hematologic cancers. It also advanced earlier candidates such as GMI-1271 and GMI-1359, reflecting a strategy built around specialized mechanisms with the potential to differentiate in niche therapeutic areas. For investors, this is an important point: GlycoMimetics has resembled a clinical-stage platform biotech, where valuation is mainly driven by trial execution, regulatory milestones, and the potential future commercial value of a lead asset rather than by recurring product revenue. ([ir.glycomimetics.com](https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-announces-results-pivotal-phase-3-study?utm_source=openai)) From a competitive perspective, GlycoMimetics operated in a highly crowded environment that includes large pharmaceutical companies, oncology-focused biotechs, and better-capitalized peers. Its theoretical edge came from its proprietary glycobiology expertise and scientific specialization, but its small scale made it vulnerable to clinical setbacks, financing pressure, and strategic uncertainty. A major recent development was the acquisition agreement announced with Crescent Biopharma in late 2024, followed by shareholder approval in June 2025 of the proposed merger and a board-approved 1-for-100 reverse stock split. The investor relations website now states that “GlycoMimetics is now Crescent Biopharma,” which indicates a significant corporate transition for the company formerly trading under GLYC. ([ir.glycomimetics.com](https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-enters-acquisition-agreement-crescent-biopharma?utm_source=openai)) Geographically, the business has been primarily U.S.-based, with core operations and corporate leadership in Maryland and a listing on NASDAQ in the United States. Recent filings also highlight the practical realities of small-cap biotech investing, including exchange compliance issues and capital structure management. For French-speaking investors, the stock should therefore be viewed as a high-risk, high-optionalitiy U.S. biotech story whose recent history is dominated less by product commercialization than by the strategic merger process with Crescent Biopharma and the associated corporate rebranding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1253689/000155837025007780/glyc-20250331x10q.htm?utm_source=openai))